Janus Henderson Group PLC cut its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 12.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,211,177 shares of the company’s stock after selling 178,066 shares during the period. Janus Henderson Group PLC owned about 0.05% of Trinity Biotech worth $3,452,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of TRIB. Renaissance Technologies LLC grew its holdings in shares of Trinity Biotech by 7.5% during the third quarter. Renaissance Technologies LLC now owns 589,209 shares of the company’s stock worth $2,357,000 after buying an additional 41,344 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Trinity Biotech during the fourth quarter worth about $141,000. Hunter Associates Investment Management LLC grew its holdings in shares of Trinity Biotech by 18.3% during the fourth quarter. Hunter Associates Investment Management LLC now owns 973,682 shares of the company’s stock worth $2,230,000 after buying an additional 150,459 shares during the last quarter. Finally, Lapides Asset Management LLC grew its holdings in shares of Trinity Biotech by 2.1% during the first quarter. Lapides Asset Management LLC now owns 655,600 shares of the company’s stock worth $1,868,000 after buying an additional 13,700 shares during the last quarter. Institutional investors own 53.78% of the company’s stock.

NASDAQ TRIB opened at $2.40 on Monday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 3.20 and a current ratio of 4.30. Trinity Biotech plc has a 52-week low of $2.13 and a 52-week high of $5.25. The stock has a market cap of $57.70 million, a P/E ratio of 20.00 and a beta of 1.52.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.06). Trinity Biotech had a positive return on equity of 3.20% and a negative net margin of 23.81%. The company had revenue of $22.03 million for the quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2019/05/20/janus-henderson-group-plc-has-3-45-million-holdings-in-trinity-biotech-plc-trib.html.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

Recommended Story: What is the Producer Price Index (PPI)?

Want to see what other hedge funds are holding TRIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trinity Biotech plc (NASDAQ:TRIB).

Institutional Ownership by Quarter for Trinity Biotech (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.